302 related articles for article (PubMed ID: 35243388)
1. Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.
Morote J; Campistol M; Triquell M; Celma A; Regis L; de Torres I; Semidey ME; Mast R; Santamaria A; Planas J; Trilla E
Eur Urol Open Sci; 2022 Mar; 37():38-44. PubMed ID: 35243388
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI.
Campistol M; Morote J; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Santamaría A; Planas J; Trilla E
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681685
[TBL] [Abstract][Full Text] [Related]
3. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
Morote J; Campistol M; Regis L; Celma A; de Torres I; Semidey ME; Roche S; Mast R; Santamaria A; Planas J; Trilla E
Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
[TBL] [Abstract][Full Text] [Related]
4. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.
Morote J; Campistol M; Celma A; Regis L; de Torres I; Semidey ME; Roche S; Mast R; Santamaría A; Planas J; Trilla E
World J Mens Health; 2022 Apr; 40(2):270-279. PubMed ID: 35021312
[TBL] [Abstract][Full Text] [Related]
6. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Proclarix in the diagnostic work-up of prostate cancer.
Kaufmann B; Fischer S; Athanasiou A; Lautenbach N; Wittig A; Bieri U; Schmid FA; von Stauffenberg F; Scherer T; Eberli D; Gorin MA; Schiess R; Poyet C
BJUI Compass; 2024 Mar; 5(2):297-303. PubMed ID: 38371198
[TBL] [Abstract][Full Text] [Related]
8. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
9. PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer.
Steuber T; Heidegger I; Kafka M; Roeder MA; Chun F; Preisser F; Palisaar RJ; Hanske J; Budaeus L; Schiess R; Keller T; Semjonow A; Hammerer P; Manka L; Ecke T; Schwentner C; Ohlmann C
Eur Urol Oncol; 2022 Jun; 5(3):321-327. PubMed ID: 33422560
[TBL] [Abstract][Full Text] [Related]
10. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
11. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
12. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
13. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
14. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
15. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
Morote J; Pye H; Campistol M; Celma A; Regis L; Semidey M; de Torres I; Mast R; Planas J; Santamaria A; Trilla E; Athanasiou A; Singh S; Heavey S; Stopka-Farooqui U; Freeman A; Haider A; Schiess R; Whitaker HC; Punwani S; Ahmed HU; Emberton M
BJU Int; 2023 Aug; 132(2):188-195. PubMed ID: 36855895
[TBL] [Abstract][Full Text] [Related]
16. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
[TBL] [Abstract][Full Text] [Related]
17. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
18. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
[TBL] [Abstract][Full Text] [Related]
19. When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy.
Lim CS; Abreu-Gomez J; Leblond MA; Carrion I; Vesprini D; Schieda N; Klotz L
Can Urol Assoc J; 2021 Apr; 15(4):115-121. PubMed ID: 33007183
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
